Form 4: Anika Therapeutics EVP David Colleran Reports Stock Transactions

David Colleran, EVP, General Counsel, and Corporate Secretary of Anika Therapeutics, reports transactions involving common stock and restricted stock units.

Summary

• On March 17, 2025, David Colleran, EVP, General Counsel, and Corporate Secretary of Anika Therapeutics, engaged in transactions involving Anika Therapeutics' common stock and restricted stock units (RSUs).
• Colleran acquired 6,448 shares of common stock upon the vesting of RSUs, which the company settled in shares.
• He also disposed of 1,893 shares to satisfy tax withholding obligations related to the vested RSUs at a price of $15.91 per share.
• Following these transactions, Colleran directly owns 47,954 shares of Anika Therapeutics' common stock.
• Additionally, Colleran holds 28,165 RSUs that vest in three equal annual installments beginning March 14, 2026, and 13,669 performance-based phantom RSUs that cliff vest on the 3rd anniversary of the grant date, subject to the Compensation Committee's determination of achievement of the award prior to the vest date.
• He also holds 12,897 RSUs that vest in three equal annual installments beginning March 15, 2025.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions, so the sentiment is neutral.

Future Outlook

The document does not contain explicit forward-looking statements, but it details the vesting schedules for various RSU grants, indicating future stock ownership changes.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It's a standard practice for executives at publicly traded companies.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly increasing the number of outstanding shares.

Key Dates